Background: Increased usage of computed tomography and magnetic resonance imaging has led to a large increase in identified pancreatic cysts of up to 25% in population-based studies. The clinical and economic relevance of identifying so many cystic lesions has not been established. Compared to other organs such as liver or kidney, dysontogenetic pancreatic cysts are rare. Pancreatic cysts comprise a variety of benign, premalignant or malignant lesions; however, precise diagnosis before resection has an accuracy of only 80%. The focus of recent research was the malignant potential of intraductal papillary mucinous neoplasms (IPMN) with the aim of establishing clinical pathways addressing risk of malignancy, age and comorbidity, treatment-related morbidity and mortality as well as cost-effectiveness of treatment and surveillance. The focus of this review is to analyze the clinical and socio-economic relevance as well as the cost-benefit relation for IPMNs. Methods: For analysis, the following MESH terms were used to identify original articles, reviews, and guidelines in PubMed: (‘intraductal papillary mucinous neoplasm' OR ‘pancreatic cysts') and (incidence OR relevance OR socio-economic OR economic OR cost-effectiveness OR cost-benefit). The retrieved publications were reviewed with a focus on clinical and socio-economic relevance in relation to the increasing incidence of IPMN. Results: Addressing the increasing prevalence of pancreatic cystic lesions, recent consensus guidelines suggested criteria for risk stratification according to ‘worrisome features' and ‘high-risk stigmata'. Recent prospective cohort studies evaluated whether these can be applied in clinical practice. Evaluation of three different clinical scenarios with regard to costs and quality-adjusted life years suggested a better effectiveness of surveillance after initial risk stratification by endoscopic ultrasound-guided fine-needle aspiration with cyst fluid analysis compared with immediate resection or follow-up without further intervention. Of interest, the ‘immediate surgery' strategy was lowest for cost-effectiveness. Conclusions: The increasing incidence of identified pancreatic cysts requires an improved strategy for non-invasive risk stratification based on advanced imaging strategies. In light of a malignancy risk of 2% for branch-duct IPMN, the socio-economic necessity of a balance between surveillance and resection has to be agreed on.

Keywords:
Intraductal papillary mucinous neoplasm, IPMN, Pancreatic cystic lesion, Cost-effectiveness, Incremental cost-effectiveness ratio, ICER, Quality-adjusted life years, QUALI
1.
Sohn TA, Yeo CJ, Camern JL, et al: Intraductal papillary mucinous neoplasms of the pancreas. An updated experience. Ann Surg 2004;239:788-799.
2.
Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y: Analysis of small cystic lesions of the pancreas. Int J Pancreatol 1995;18:197-206.
3.
Kimura W: How many millimeters do atypical epithelia of the pancreas spread intraductally before beginning to infiltrate? Hepatogastroenterology 2003;50:2218-2224.
4.
Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH: Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008;191:802-807.
5.
Lee KS, Sekhar A, Rofsky NM, Pedrosa I: Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010;105:2079-2084.
6.
Bülow R, Simon P, Thiel R, et al: Anatomic variants of the pancreatic duct and their clinical relevance: an MR-guided study in the general population. Eur Radiol 2014;24:3142-3149.
7.
Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB: The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2012;10:555-558.
8.
Gardner TB, Glass LM, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Tsapakos MJ, Suriawinata AA, Tsongalis GJ, Pipas JM, Gordon SR: Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in United States adults. Am J Gastroenterol 2013;108:1546-1550.
9.
Klibansky DA, Reid-Lombardo KM, Gordon SR, et al: The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2012;10:555-558.
10.
Canto MI, Hruban RH, Fishman EK, et al: Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804.
11.
Kosmahl M, Pauser U, Anlauf M, et al: Cystic pancreas tumors and their classification: features old and new (article in German). Pathologe 2005;26:22-30.
12.
Kloppel G, Kosmahl M, Luttges J: Intraductal neoplasms of the pancreas: cystic and common (article in German). Pathologe 2005;26:31-36.
13.
Nagai K, Doi R, Kida A, et al: Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg 2008;32:271-278; discussion 279-280.
14.
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S; International Association of Pancreatology: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
15.
Khalid A, Brugge W: ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007;102:2339-2349.
16.
Distler M, Kersting S, Niedergethmann M, et al: Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg 2013;258:324-330.
17.
Kloppel G, Basturk O, Schlitter AM, Konukiewitz B, Esposito I: Intraductal neoplasms of the pancreas. Semin Diagn Pathol 2014;31:452-466.
18.
Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.
19.
Aso T, Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Tamura K, Ideno N, Osoegawa T, Takahata S, Shindo K, Ushijima Y, Aishima S, Oda Y, Ito T, Mizumoto K, Tanaka M: ‘High-risk stigmata' of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2014;43:1239-1243.
20.
Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Ferrone CR, Sahani D, Pitman MB, Warshaw AL, Lillemoe KD, Fernandez-del Castillo CF: Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013;258:466-475.
21.
Kanno A, Satoh K, Hirota M, et al: Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 2010;45:952-959.
22.
Fritz S, Hackert T, Hinz U, et al: Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 2011;98:104-110.
23.
Salvia R, Crippa S, Falconi M, et al: Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 2007;56:1086-1090.
24.
Tanno S, Nakano Y, Nishikawa T, et al: Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long term follow-up results. Gut 2008;57:339-343.
25.
Woo SM, Ryu JK, Lee SH, et al: Branch duct intraductal papillary mucinous neoplasms in a prospective series of 190 patients. Br J Surg 2009;96:405-411.
26.
Uehara H, Ishikawa O, Katayama K, et al: Size of mural nodule as an indicator of surgery for branch-duct intraductal papillary mucinous neoplasm of the pancreas during follow-up. J Gastroenterol 2011;46:657-663.
27.
Maguchi H, Tanno S, Mizuno N: Natural history of branch duct intraductal papillary mucinous neoplasm: a multicenter study in Japan. Pancreas 2011;40:364-370.
28.
Tang RS, Weinberg B, Dawson DW, et al: Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008;6:815-819; quiz 719.
29.
Pelaez-Luna M, Chari ST, Smyrk TC, et al: Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102:1759-1764.
30.
Huang ES, Gazelle GS, Hur C: Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis. Dig Dis Sci 2010;55:852-860.
31.
Provenzale D, Lipscomb J: Cost-effectiveness: definitions and use in the gastroenterology literature. Am J Gastroenterol 1996;91:1488-1493.
32.
Pignone M, Saha S, Hoerger T, Mandelblatt J: Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
33.
Lerch MM, Braun J, Harder M, et al: Posteroperative adaptation of the small intestine after total colectomy and J-pouch-anal anastomosis. Dis Colon Rectum 1989;32:600-608.
34.
Das A, Ngamruengphong S, Nagendra S, Chak A: Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. Gastrointest Endosc 2009;70:690-699.
35.
Arias E: United States life tables, 2003. Natl Vital Stat Rep 2006;54:1-40.
36.
Khalid A, Brugge W: ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007;102:2339-2349.
37.
Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72-79.
38.
Yamaguchi K, Kanemitsu S, Hatori T, Maguchi H, Shimizu Y, Tada M, Nakagohri T, Hanada K, Osanai M, Noda Y, Nakaizumi A, Furukawa T, Ban S, Nobukawa B, Kato Y, Tanaka M: Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 2011;40:571-580.
39.
Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y: Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol 2014;21:2444-2452.
© 2014 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.